Titan Pharmaceuticals Inc. Common Stock
(NASDAQ:TTNP)
Description
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.
TTNP Overview
None
Sector |
Health Care |
Industry |
Biotechnology: Biological Products (No Diagnostic Substances) |
Previous Close |
$0.5490 |
Previous Close Volume |
50160 |
Latest News
- Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq 27 Nov 2024 16:06:24
- Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd. 19 Aug 2024 16:38:45
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria 25 Jan 2024 16:40:13
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio 28 Dec 2023 17:05:53
- Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets 27 Jul 2023 16:22:15